Remove 2019 Remove Dermatitis Remove Eczema
article thumbnail

FDA, EMA Accept Galderma’s BLA for Nemolizumab for PN and AD

The Dermatology Digest

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). Galderma is planning for multiple regulatory submissions in 2024.

article thumbnail

White spots on skin: Pictures, causes, treatment

First Derm

It is considered a mild form of eczema. You should try to avoid trauma to the skin and make sure to wear sunscreen SPF 30 or greater with UVA and UVB protection every day.This could also be PITYRIASIS ALBA ( hypopigmentation of the skin from skin sensitivity or eczema). Pityriasis alba commonly occurs on the face and extremities.

article thumbnail

Rash on Butt: Causes, Diagnosis, and Treatment

First Derm

Contact dermatitis Contact dermatitis is a common type of rash. Some contact dermatitis rashes appear immediately, There are two types: allergic contact dermatitis and irritant contact dermatitis. Atopic dermatitis is the most prevalent kind of eczema and is commonly referred to simply as eczema.

article thumbnail

Study: Air Pollution Triggers Summer AD Surge

The Dermatology Digest

Air pollution may contribute to the development or worsening of skin conditions such as atopic dermatitis and eczema, according to researchers out of Massachusetts General Hospital (MGH). ppm in the months of May–September in 2019–2022 rose to 0.6 Carbon monoxide concentrations that were an average of 0.22 ppm in July of 2023.

Eczema 36
article thumbnail

Could Your Itchy Feet be a Sign of a Bigger Health Issue?

First Derm

Skin-related causes include athlete’s foot, eczema, psoriasis, contact dermatitis, scabies, and fungal infections. Eczema can affect various parts of the body, including the feet. Eczema can affect various parts of the body, including the feet. In severe cases, eczema can cause painful cracks and blisters.

Eczema 52
article thumbnail

Nemolizumab Update: Galderma’s IL-31 Blocker Continues to Wow in PN, AD

The Dermatology Digest

In addition, results from the phase III ARCADIA clinical trials in atopic dermatitis (AD) found that nemolizumab-treated patients who responded at 16 weeks maintained skin and itch responses through to week 48, even when dosing was reduced from every four to every eight weeks.

article thumbnail

Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD

The Dermatology Digest

The comprehensive safety analysis establishes evidence regarding the safety of systematic Janus kinase inhibitors in patients with atopic dermatitis. They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022.

Safety 36